Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urinary urgency, frequency and incontinence in adult patients. GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is indicated for conditions affecting bladder storage function within the overactive bladder disease family. - Overactive bladder: reduces urgency episodes and increases bladder capacity. - Urinary urgency: lessens sudden strong urges to void. - Urinary frequency: decreases the number of daily voids, improving quality of life.

Adverse reactions may occur with mirabegron therapy.

Common Side Effects: - Hypertension: elevated blood pressure readings. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Urinary tract infection: signs of bladder infection. - Headache: mild to moderate head pain. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Tachycardia: rapid heart rate. - Severe hypertension: markedly high blood pressure requiring medical attention. - Angioedema: swelling of face, lips or throat. - Allergic reactions: rash, itching or anaphylaxis.

Before initiating therapy, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiovascular disease: observe blood pressure and heart rate regularly. - Concomitant anticholinergics: evaluate additive urinary effects. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirabegron may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase mirabegron exposure. - Narrow‑gap antihypertensives (e.g., beta‑blockers): may reduce blood‑pressure‑lowering effect. - Monoamine oxidase inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive response. - Anticholinergics: additive effect on urinary retention. - Other β3‑agonists: potential for overlapping pharmacodynamic activity.